Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5605712 | 0.96 | CCR2 (0.36) | HCAR2CCR2GAAALDH1A1SLC6A2 | |
| SCHEMBL28417608 | 0.71 | CCR2 (0.40) | CCR2SLC6A2SLC6A3 | |
| SCHEMBL12484267 | 0.69 | NPSR1 (0.43) | CCR2MAPK1LMNA | |
| SCHEMBL5244036 | 0.69 | NPSR1 (0.43) | CCR2MAPK1LMNA | |
| SCHEMBL337275 | 0.68 | CCR2 (0.36) | CCR2SLC6A2 | |
| SCHEMBL7799804 | 0.65 | L3MBTL1 (0.42) | CCR2LMNAL3MBTL1 | |
| SCHEMBL3264515 | 0.65 | MAPT (0.30) | HCAR2 | |
| SCHEMBL11437597 | 0.65 | CCR2 (0.34) | CCR2 | |
| SCHEMBL5605715 | 0.64 | HCAR2 (0.39) | HCAR2CCR2ALDH1A1 | |
| SCHEMBL11370920 | 0.64 | OPRM1 (0.40) | GAASLC6A2MAPK1LMNASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169950-B2 | Method for producing monocarbonyl compounds or biscarbonyl compounds or hydroxyl compounds | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-01-30 | — | — | US | disclosed |
| US-20040073041-A1 | Method for producing monocarbonyl compounds or biscarbonyl compounds or hydroxyl compounds | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2004-04-15 | — | — | US | disclosed |
| US-5939580-A | Process for preparing glyoxylic esters and their hydrates | DSM FINE CHEMICALS AUSTRIA GMBH (AT) | 1999-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073041-A1 | Method for producing monocarbonyl compounds or biscarbonyl compounds or hydroxyl compounds | OXER1, FHIT, HAO2 | HCAR2 89/4885CCR2 2672/4885GAA 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.